Q-omics provides the consensus-scored KCNJ10 profile across patient tissues and cancer cell-line models. KCNJ10 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, KCNJ10 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, KCNJ10 RNA expression shows 16,298 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where KCNJ10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNJ10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNJ10 survival associations across molecular data types. KCNJ10 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNJ10 RNA expression–survival associations across cancer types. High KCNJ10 expression shows favorable associations in HNSC, OV, CESC, LGG, SKCM and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for KCNJ10 RNA expression.
This table summarizes KCNJ10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KCNJ10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNJ10 shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in LUAD, BRCA and HNSC. The KIRC box plot shows higher KCNJ10 RNA expression in normal versus tumor tissue (log2 FC = −5.343, t-test p < 0.001).
This table shows molecular features associated with KCNJ10 in patient tissues and cancer cell lines. In patient samples, KCNJ10 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNJ10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SKIN.
